Rod Raynovich
Rod Raynovich
Send Message
Rod Raynovich
Stop FollowingRod Raynovich
View as an RSS Feed
- Emerging Biomarker Companies Redux: Positioned For Growth
- Biotech Stocks Get A Turbo Boost From Vertex
- Is There No End To The Biotech Bull Market?
- Biopharmaceutical Sector Attempts Another Move To New Highs
- Biotech Bull Market: Are ETFs Better Than Mutual Funds?
- Update On Emerging Biomarker Diagnostics: BG Medicine, Response Genetics, Vermillion
- Who Knows About The Bull Market In Biotech Stocks?
- Biotech Sector Avoids Nasty Correction And Hits New Highs
- Consolidation Continues In Mid Cap DX Companies: Bull Market In Biotech Hits New Highs
- Emerging Biomarker Diagnostics: BGMedicine And Vermillion
- Biotech Bull Market Intact: Rayno Biopharmaceutical Portfolio Outperforms
- Response Genetics Stock Soars 31% On $7.8M Offering News
- Technology Convergence Trends in the Biopharma Sector: Abbott, Alere and Merge
- Life Science Portfolios: Reflecting on a Year of Out-Performance
- Explore the Many Flavors of Healthcare Stocks: Biotech, Drugs, Life Sciences, MedTech
- Balance Your Portfolio With Three Stable Biotech ETFs
- Novel Diagnostic Tests Utilizing Biomarkers Working Well for Vermillion
- Cardiovascular Systems Gains Traction
- Immucor Cuts Guidance on Lower Demand
- Successful IPOs in Genomics Could Ignite Biotech Stocks
- AACC Meeting Buzz Fuels Rally in Diagnostics
- Gilead Holding Up on Exhaustion of Negativity
- Biomarker Diagnostics Drive Personalized Medicine but Path to Market Still Rife With Hurdles
